8月16日到22日，全球医药市场共完成了5项授权和合作协议，中国医药市场占了4项，包括3项出海交易和1项国内交易。其中最引人注目的交易是默沙东行使独家选择权，引进科伦博泰一临床前双抗资产，首付3750万美元。此外，普众发现将一款ADC资产授权给Adcendo。
在全球范围内，仅签署了一项协议，SciSparc与Polyrizon就前者的临床前资产THX-160达成授权交易。
Between August 16 and 22, a total of five licensing and cooperation deals were signed globally, with four of them occurring within the China Biotech Industry. Notably, Kelun-Biotech and Merck & Co. entered into an out-licensing agreement for a pre-clinical stage asset, involving an upfront payment of $37.5 million. Additionally, Multitude Therapeutics and Adcendo secured an out-licensing deal for an Antibody-Drug Conjugate (ADC).
On the global stage, only one other licensing deal was reported, involving SciSparc and Polyrizon for the pre-clinical stage asset THX-160.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
